Long-term use of the boosted protease inhibitor darunavir (Prezista) modestly increases the risk of cardiovascular disease, according to data from the ongoing D:A:D study presented to the recent Conference on Retroviruses and Opportunistic Infections. Investigators identified an independent association between cumulative use of the drug over 5 years and heart attack and stroke.
HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. This finding may help explain how an antibody against alpha-4 beta-7 produced sustained viral remission in monkeys.
Specialized services to attract men to HIV testing and treatment may need to adopt several different formats in order to reach different sub-populations of men, suggesting there is no single service innovation that will boost uptake among men in sub-Saharan Africa, according to research from South Africa presented at last month’s Conference on Retroviruses and Opportunistic Infections.
After 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. Another study showed that people with low bone density who switched from TDF to TAF saw improved bone health, including a reduction in osteoporosis.